John Docherty - Apr 26, 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
President, Director
Signature
/John Docherty/
Stock symbol
LEXX
Transactions as of
Apr 26, 2024
Transactions value $
$0
Form type
4
Date filed
5/10/2024, 04:34 PM
Previous filing
Oct 30, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 54.1K Apr 26, 2024 Private Holding Company

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +49.5K +39.71% $0.00 174K Apr 26, 2024 Common Shares 49.5K $2.36 Direct
holding LEXX Stock Options 13.3K Apr 26, 2024 Common Shares 13.3K $3.00 Direct F1
holding LEXX Stock Options 31.3K Apr 26, 2024 Common Shares 18K $3.00 Direct F2
holding LEXX Stock Options 49.7K Apr 26, 2024 Common Shares 18.3K $3.00 Direct F3
holding LEXX Stock Options 64.7K Apr 26, 2024 Common Shares 15K $3.00 Direct F4
holding LEXX Stock Options 94.7K Apr 26, 2024 Common Shares 30K $2.91 Direct
holding LEXX Stock Options 125K Apr 26, 2024 Common Shares 30K $1.15 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023
F2 Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
F3 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F4 Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023